

Disclosures

Personal Commercial (8)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen Inc.	Other - Stock ownership	Significant (>= \$5,000)	General Cardiology
Asahi	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
BRAVO4Health	Ownership Interest/Partnership/Principal	Significant (>= \$5,000)	General Cardiology
Microbiome Technologies	Other - Stock Options	None (\$0)	Prevention
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Sanofi	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Takeda	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (2)

Trial Name	Trial Sponsor	Trial Funding Source
Figaro and fidelio	Bayer Healthcare Pharmaceuticals	
Diabetic Nephropathy	Boehringer Ingelheim Pharmaceuticals, Inc	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2015	Lipitor and Diabetes	Defendant	Accusation is that Lipitor may cause diabetes	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 11/28/2018

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/28/2018

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 11/28/2018

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 11/28/2018

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.